Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
scPharmaceuticals Inc (SCPH)
NASDAQ:SCPH
Holding SCPH?
Track your performance easily
SCPH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.08 - $6.71
Previous Close$3.35
Volume294.85K
Average Volume (3M)349.42K
Market Cap
$167.63M
Enterprise Value$128.63M
Total Cash (Recent Filing)$91.50M
Total Debt (Recent Filing)$52.50M
Price to Earnings (P/E)―
Beta1.34
Next Earnings
Mar 19, 2025EPS Estimate
-$0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.91
Shares Outstanding50,040,134
10 Day Avg. Volume816,797
30 Day Avg. Volume349,417
Standard Deviation0.17
R-Squared0.00181
Alpha0.00849
Financial Highlights & Ratios
Price to Book (P/B)5.51
Price to Sales (P/S)5.82
Price to Cash Flow (P/CF)-2.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.25
Enterprise Value/Gross Profit13.15
Enterprise Value/Ebitda-2.27
Forecast
1Y Price Target
$19.00Price Target Upside467.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
scPharmaceuticals News
PremiumCompany Announcements
scPharmaceuticals Reports Strong Growth in Q3 2024
PremiumCompany Announcements
scPharmaceuticals Secures Funding, Advances FUROSCIX CommercializationBulls Say, Bears Say
Bulls Say
Financial StrengthScPharma is well-capitalized to execute US launches for Furoscix in both heart failure and potentially chronic kidney disease, with recent financings adding significant funds to their cash position.
Market AdoptionManagement’s various initiatives to accelerate Furoscix sales trajectory are now coming to fruition, with positive reception and adoption observed.
Product ApprovalThe FDA accepted the company’s sNDA to expand the Furoscix indication to include treatment of edema due to fluid overload in patients with CKD.
Bears Say
DemandThe 'donut hole' comes back to bite Furoscix, with 3Q coming in a little light relative to expectations, negatively affecting demand.
Financial PerformanceHigher than expected number of Medicare patients remained in the coverage gap, resulting in higher rebates and fill rates affected by high copays.
RevenueShares are trading down ~13% due to the lower than expected revenue which was mostly due to Medicare coverage gap patients being unable or unwilling to fill scripts.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
SCPH FAQ
What was scPharmaceuticals Inc’s price range in the past 12 months?
scPharmaceuticals Inc lowest stock price was $3.08 and its highest was $6.71 in the past 12 months.
What is scPharmaceuticals Inc’s market cap?
Currently, no data Available
When is scPharmaceuticals Inc’s upcoming earnings report date?
scPharmaceuticals Inc’s upcoming earnings report date is Mar 19, 2025 which is in 113 days.
How were scPharmaceuticals Inc’s earnings last quarter?
scPharmaceuticals Inc released its earnings results on Nov 13, 2024. The company reported -$0.75 earnings per share for the quarter, missing the consensus estimate of -$0.298 by -$0.452.
Is scPharmaceuticals Inc overvalued?
According to Wall Street analysts scPharmaceuticals Inc’s price is currently Undervalued.
Does scPharmaceuticals Inc pay dividends?
scPharmaceuticals Inc does not currently pay dividends.
What is scPharmaceuticals Inc’s EPS estimate?
scPharmaceuticals Inc’s EPS estimate is -$0.34.
How many shares outstanding does scPharmaceuticals Inc have?
scPharmaceuticals Inc has 50,040,134 shares outstanding.
What happened to scPharmaceuticals Inc’s price movement after its last earnings report?
scPharmaceuticals Inc reported an EPS of -$0.75 in its last earnings report, missing expectations of -$0.298. Following the earnings report the stock price went down -14.066%.
Which hedge fund is a major shareholder of scPharmaceuticals Inc?
Among the largest hedge funds holding scPharmaceuticals Inc’s share is Woodline Partners LP. It holds scPharmaceuticals Inc’s shares valued at 2M.
---
scPharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.00 (467.16% Upside)
$19.00 (467.16% Upside)
Blogger Sentiment
Bullish
SCPH Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 501.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.2%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.97%
12-Months-Change
Fundamentals
Return on Equity
-200.65%
Trailing 12-Months
Asset Growth
17.88%
Trailing 12-Months
Company Description
scPharmaceuticals Inc
scPharmaceuticals, Inc.engages in the development of transformative pharmaceutical products for subcutaneous delivery. Its products include furosemide, used as parenteral diuretic in treating heart failure and ceftriaxone, used as parenteral antibiotic outside the hospital setting. The company was founded by Pieter Muntendam and Bertram Pitt in February 2013 and is headquartered in Burlington, MA.
---
SCPH Earnings Call
Q3 2024
0:00 / 0:00
---
SCPH Stock 12 Month Forecast
Average Price Target
$19.00
▲(467.16% Upside)
Technical Analysis
Best Analysts Covering SCPH
1 Year
1 Year Success Rate
6/18 ratings generated profit
1 Year Average Return
-3.96%
reiterated a buy rating 13 days ago
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -3.96% per trade.
---